Recent News

• 05.01.2025 - Q1 2025 Ascendis Pharma Earnings Conference Call
• 05.01.2025 - Q1 2025 Ascendis Pharma Earnings Conference Call
• 04.24.2025 - Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
• 04.24.2025 - Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
• 04.24.2025 - Ascendis Pharma to Report First Quarter 2025 Financial Results and Provide Business Update on May 1, 2025
• 03.31.2025 - Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
• 03.31.2025 - Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
• 03.31.2025 - Ascendis Submits U.S. NDA for TransCon CNP (Navepegritide) for the Treatment of Children with Achondroplasia
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference
• 03.04.2025 - TD Cowen 45th Annual Health Care Conference

Recent Filings

• 04.09.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.31.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.20.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.12.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 03.07.2025 - 144 Report of proposed sale of securities
• 03.06.2025 - 144 Report of proposed sale of securities
• 03.06.2025 - 144 Report of proposed sale of securities
• 03.05.2025 - 144 Report of proposed sale of securities
• 03.05.2025 - 144 Report of proposed sale of securities